NCIC CLINICAL TRIALS GROUP

TESTES AND KIDNEY

GU DISEASE ORIENTED GROUP MEETING AGENDA

Eaton Chelsea Hotel, Toronto, ON

ROOM: AUSTEN

SATURDAY MAY 3RD, 2014, 7:00 AM – 8:00 AM

CO-CHAIRS: J. KNOX, A. KAPOOR, C. KOLLMANNSBERGER & P. CHUNG

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies (renal and testicular cancer) in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

7:00 am Welcome

Studies Updates

7:02 am NEXT: REC2 follow-up study. J. Knox

7:05 am Neoadjuvant study (ECOG 1812, 1813). J. Knox /A. Kapoor

7:20 am Oligo mets study G. Bjarnason

7:25 am Partial nephrectomy ischemia study update. I. Cagiannos

continued on next page ...
New Study Proposal

7:30 am  Concept A031102, “A randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high-dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors.”

P.Chung

7:45 am  New concept/proposals developments  All

8:00 am  Meeting Adjourned